July 15, 2021 -- GentiBio and Forge Biologics have formed a strategic development and manufacturing partnership to advance GentiBio's immune tolerance platform.
Under the agreement, Forge, a cell and gene therapy-focused contract development and manufacturing organization (CDMO), will provide adeno-associated viral (AAV) vector process and analytical development, scale-up engineering, and good manufacturing practice (GMP) manufacturing services for GentiBio's therapeutic candidates based on the company's engineered T regulatory cells (Tregs).
GentiBio's autologous and allogeneic EngTregs platform restores immune tolerance to overcome major limitations in existing Tregs therapeutics.
GentiBio's process development will utilize Forge's Blaze Vector production platform as well as HEK 293 suspension ignition cells. All development and GMP activities will take place at Forge's 175,000-sq-ft facility in Columbus, OH.
Financial details of the partnership were not disclosed.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: